Johnson & Johnson (NYSE:JNJ) is up 4% premarket on light volume in reaction to its announcement that it has selected a lead COVID-19 vaccine candidate.
A Phase 1 clinical trial should launch in
September. The first batches of product could be available for emergency
use in early 2021.
It plans to establish new U.S. vaccine manufacturing capabilities and additional capacity ex-U.S.
https://seekingalpha.com/news/3556197-j-and-j-picks-lead-covidminus-19-vaccine-candidate-shares-gain
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.